Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
AstraZeneca
McKinsey
Colorcon
Johnson and Johnson

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR STRATTERA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Strattera

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00174226 ↗ Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar Completed Pfizer Phase 2 2004-11-01 Determine if there is a difference in treatment response for adults with ADHD who are treated with Strattera versus those treated with a combination of Strattera and buspirone
NCT00181766 ↗ Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS) Completed Eli Lilly and Company Phase 4 2003-12-01 This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the treatment of adults with attention deficit hyperactivity disorder not otherwise specified. The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day, whichever is less) in adults with ADHD NOS will be safe and well tolerated.
NCT00181766 ↗ Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS) Completed Massachusetts General Hospital Phase 4 2003-12-01 This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the treatment of adults with attention deficit hyperactivity disorder not otherwise specified. The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day, whichever is less) in adults with ADHD NOS will be safe and well tolerated.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Strattera

Condition Name

Condition Name for Strattera
Intervention Trials
Attention Deficit Hyperactivity Disorder 35
Attention Deficit Disorder With Hyperactivity 7
ADHD 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Strattera
Intervention Trials
Attention Deficit Disorder with Hyperactivity 54
Hyperkinesis 42
Disease 34
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Strattera

Trials by Country

Trials by Country for Strattera
Location Trials
United States 175
United Kingdom 22
Spain 16
Germany 12
Canada 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Strattera
Location Trials
New York 11
California 8
Tennessee 8
Ohio 8
Massachusetts 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Strattera

Clinical Trial Phase

Clinical Trial Phase for Strattera
Clinical Trial Phase Trials
Phase 4 29
Phase 3 16
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Strattera
Clinical Trial Phase Trials
Completed 72
Terminated 6
Unknown status 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Strattera

Sponsor Name

Sponsor Name for Strattera
Sponsor Trials
Eli Lilly and Company 35
National Institute of Mental Health (NIMH) 6
National Institute on Drug Abuse (NIDA) 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Strattera
Sponsor Trials
Other 82
Industry 46
NIH 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Medtronic
Johnson and Johnson
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.